[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatitis-c-hcv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatitis-c-hcv":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,76,106,129,162,188,214,245,265],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644289","hepatitis-c-pharmacist-physician-patient-navigator-collaborative-care-model-in-permanent-supportive-housing-100644289",false,"NCT07667101","Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive Housing","A Hybrid Implementation-Effectiveness Study of the Pharmacist, Physician, and Patient Navigator Collaborative Care Model (PPP-CCM) to Cure Hepatitis C Among Persons Who Use Drugs With Housing Insecurity","HepP3","Inclusion Criteria:\n\n* Adult ≥18 years of age\n* Currently a resident at one of DESC's PSH buildings at the time of study enrollment\n* Positive HCV test documented (screening antibody test or viral load test)\n* Provides release of information (ROI) to access community pharmacy electronic medical records (EHR) and\u002For other HCV treatment providers for information on HCV care during the study period between baseline visit and 24-month visit\n\nExclusion Criteria:\n\n* Taking medications to treat HCV at the start of the study\n* Cognitive impairment (acute or chronic) resulting in inability to provide informed consent\n* Currently or impending incarceration\n* People who plan to leave the Seattle area within 24 months\n* Not English speaking\n* Behavioral risk posing safety concerns per discretion of research staff","ALL","18 Years",{"count":20,"type":21},444,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this study is to extend our prior research by conducting a pragmatic implementation trial using a parallel-group, cluster randomized design to evaluate the PPP-CCM's ability to improve access to DAAs for HCV within a network of permanent supportive housing (PSH) buildings in Seattle and King County. The study will implement PPP-CCM to 16 housing buildings, randomizing half to receive PPP-CCM (intervention) versus usual care (UC) for 12-months, after which all buildings will have access to PPP-CCM. All buildings will have access to point-of-care HCV screening for the first 6 months of the study. Study outcome data will be collected through a longitudinal cohort-study of persons who screened positive for HCV which will conduct surveys and review of medical records at baseline, 12- and 24-months.",[27],"HEPATITIS C (HCV)","RECRUITING","2026-06-18",{"date":31,"type":32},"2026-06-24","ACTUAL",{"date":34,"type":32},"2026-06-01",{"date":36,"type":21},"2029-06",{"name":38,"class":39},"University of Washington","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":50,"conditions":51,"keywords":57,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":40},"100643749","pilot-study-of-an-adapted-partner-navigation-intervention-booster-session-for-sustained-healthcare-engagement-among-people-who-inject-drugs-100643749","NCT07631559","Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs","Inclusion criteria:\n\nFor index participants:\n\n* 18 years of age or older at enrollment\n* History of injecting drug use\n* Completed HCV treatment within the past 3 months\n* Report a primary injecting partner willing to participate\n* Willing and able to provide informed consent\n* English or Spanish speaking\n\nFor primary injecting partners:\n\n* Primary injecting partner of an enrolled index participant:\n* 18 years of age or older at enrollment\n* Willing and able to provide informed consent\n* English or Spanish speaking\n* has context menu\n\nExclusion criteria:\n\nFor both index participants and injecting partners:\n\n* Unable to provide informed consent due to cognitive impairment or acute intoxication at the time of enrollment\n* Previously participated in this study in any capacity",{"count":48,"type":21},50,[24],"This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject drugs (PWID) and their injecting partners in San Francisco. The proposed research includes secondary analyses of existing trial data, additional survey measures, qualitative interviews, and a pilot intervention adaptation.\n\nThe study has two primary objectives. First, it examines how racialized discrimination (structural, interpersonal, and internalized) affects HCV treatment initiation and dyadic partner support processes within injecting partnerships. Second, it evaluates whether a brief, adapted \"booster\" partner navigation session delivered at HCV treatment completion can improve engagement in ongoing healthcare.\n\nParticipants include adults (≥18 years) who inject drugs and have been diagnosed with HCV, along with their primary injecting partners. Study activities include longitudinal surveys, qualitative interviews with a subset of participants, and a pilot intervention session with follow-up evaluation.\n\nThis research addresses critical gaps in understanding how social relationships and structural inequities influence healthcare engagement among PWID. Findings will inform culturally responsive adaptations to dyadic interventions and improve continuity of care in a population disproportionately affected by HCV and systemic barriers to healthcare.",[27,52,53,54,55,56],"Opioid Use Disorder","Substance Use Disorder (SUD)","Drug Use Disorders","Healthcare Access","Harm Reduction",[58,59,60,61,62,63,64,65,66],"People who inject drugs (PWID)","Partner navigation","Dyadic intervention","Post-treatment healthcare engagement","Behavioral intervention","HCV treatment","Injecting partnerships","Feasibility pilot","Substance use","NOT_YET_RECRUITING",{"date":69,"type":32},"2026-06-08",{"date":71,"type":21},"2026-09-01",{"date":73,"type":21},"2027-06-30",{"name":75,"class":39},"University of California, San Francisco",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100636004","phase-4-combating-related-epidemics-in-hcv-100636004","NCT07560046","Combating Related Epidemics in HCV","Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations","CREST","Inclusion Criteria:\n\n1. Can provide written informed consent or assent\n2. Minimum of 16 years of age\n3. Willing to undergo HIV, HCV, HBV testing\n4. Willing to undergo treatment for HCV and complete study activities\n\nExclusion Criteria:\n\n1. History of HCV treatment for current infection\n2. Known preexisting (evidence or history of) decompensated liver disease based on: medical diagnosis through medical record, reporting by the participant, or clinical evidence per the site PI\n3. Contraindication for treatment with sofosbuvir\u002Fvelpatasvir due to allergy or drug-drug interaction including use of any prohibited concomitant medications within 28 days prior to study entry.\n4. History of clinically significant illness or any other major medical disorder that may interfere with participant treatment, assessment, or compliance with study requirements as determined by the site PI\n5. Ongoing need for use of daily proton pump inhibitor (PPI) at doses ≥40 mg of omeprazole (or equivalent). NOTE: PPI can be discontinued or dose reduced to 20 mg\u002Fday of omeprazole (or equivalent) at time of study entry.\n\nRetreatment Inclusion Criteria:\n\n1. Completion of sofosbuvir\u002Fvelpatasvir treatment regimen as enrolled participant in CREST and willingness to receive retreatment. FIB-4 \\& CTP score available within 90-days of retreatment initiation.\n2. Meeting any of the below criteria during post-cessation treatment follow-up. Relapse, defined as HCV RNA \\\u003CLLOQ\u002FD (TD or TND) during and\u002For at end of treatment followed by HCV RNA \\>LLOQ\u002FD or target detected based on qualitative POC test at any time point from end of treatment to 12 weeks after end of treatment OR Re-infection, defined as meeting the primary outcome criteria for SVR4+ followed by HCV RNA \\>LLOQ\u002FD or target detected based on qualitative POC test at any time point beyond meeting SVR4+ OR Post-treatment virologic failure, defined as HCV RNA \\>LLOQ\u002FD at any point after end of treatment (after week 24 visit) or during follow-up, not otherwise meeting definition of relapse or re-infection\n\nRetreatment Exclusion Criteria:\n\n1. Known preexisting (evidence or history of) decompensated liver disease based on: medical diagnosis through medical record, reporting by the participant, clinical evidence per the site PI, or by CTP score ≥7.\n2. Pregnant or breast feeding at time of retreatment with sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir.\n3. Contraindication for treatment with sofosbuvir\u002Fvelpatasvir (reinfection) or sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir (relapse or virologic failure) due to FDA package insert, allergy, or drug-drug interaction including use of any prohibited concomitant medications within 28 days prior to study entry.\n4. History of clinically significant illness or any other major medical disorder that may interfere with participant treatment, assessment, or compliance with study requirements as determined by the site PI\n5. Ongoing need for use of daily proton pump inhibitor (PPI) at doses ≥40 mg of omeprazole (or equivalent.). NOTE: PPI can be discontinued or dose reduced to 20 mg\u002Fday of omeprazole (or equivalent) at time of study entry.","16 Years",{"count":86,"type":21},1280,[88],"PHASE4","This is a two-arm cluster randomized control trial to evaluate the effectiveness of a single-visit point-of-care (POC) test and treat bundle (intervention arm) compared to the current standard-of-care (SOC, control arm). 1:1 randomization occurs at the site level.",[91,92,27],"HIV - Human Immunodeficiency Virus","Hepatitis B Virus (HBV)",[94,95,96,82],"Hepatitis C","Hepatitis B","HIV","2026-04-30",{"date":99,"type":32},"2026-05-05",{"date":101,"type":21},"2026-08-01",{"date":103,"type":21},"2030-12-30",{"name":105,"class":39},"Duke University",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":127,"locationsCount":40},"100513676","persuasive-health-communication-intervention-for-hivhcv-100513676","NCT05968573","Persuasive Health Communication Intervention for HIV\u002FHCV","Evaluation of a Persuasive Health Communication Intervention Designed to Increase HIV\u002FHCV Screening Among Emergency Departments Patients Who Currently, Formerly or Never Injected Drugs.","Inclusion Criteria:\n\n* ≥18 years-old\n* Speak English or Spanish, and able to provide informed consent for study participation\n* Not HIV AND HCV infected\u002FAntibody+ (per EHR review and patient report)\n* Not already participating in a HIV or HCV study (e.g., HIV PrEP, HIV vaccine)\n* Not tested for HIV OR HCV within the past 12 months (per EHR review and patient report)\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* Unable to speak Spanish or English\n* HIV or HCV positive\n* Currently enrolled in another HIV or HCV research study\n* Has tested for HIV or HCV in the past 12 months",true,{"count":115,"type":21},2000,[24],"A major impediment to emergency department (ED)-based HIV\u002FHCV screening success is that often ED patients at risk for, or later diagnosed with, HIV and HCV decline testing. In this R01 project, the research team will assess how well a promising, easy-to-use, one-time, minimal-training-needed, very brief persuasive health communication intervention (PHCI) increases acceptance of testing among adult ED patients who either currently, formerly or never injected drugs and initially declined HIV\u002FHCV screening. The research team will conduct a randomized, controlled trial (RCT) at EDs within the Mount Sinai Health System to compare the efficacy of the PHCI when delivered by a video vs. an HIV\u002FHCV counselor. Patients who initially declined HIV\u002FHCV screening will be stratified by injection-drug use (IDU) history cohorts: (1) current\u002Fformer PWIDs, (2) never\u002Fnon-PWIDs. Within each IDU history cohort, the research team will randomly assign participants (1:1:1) to a PHCI delivered by: (1) a video with captions, (2) a video without captions, (3) an HIV\u002FHCV counselor. This R01 project will be conducted at Mount Sinai affiliate hospitals EDs. For Aim 2, the research team will determine if screening acceptance is similar across IDU history cohorts. For Aim 3, the research team will further compare the two delivery forms of the PHCI through a health economics assessment, both independent of IDU history and within each IDU history cohort.",[119,120],"Human Immunodeficiency Virus (HIV)","Hepatitis C (HCV)","2026-04-02",{"date":123,"type":32},"2026-04-08",{"date":125,"type":32},"2023-12-04",{"date":101,"type":21},{"name":128,"class":39},"University of South Florida",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":40},"100589366","phase-4-implementing-low-barrier-hcv-treatment-in-a-jail-setting-100589366","NCT06953479","Implementing Low-Barrier HCV Treatment in a Jail Setting","MINMON-J: An Effectiveness Implementation Pilot Study Evaluating a Low-barrier Hepatitis C Treatment Model in a Jail Setting","MINMON-J","Inclusion Criteria:\n\n* Incarcerated individual at RIDOC\n* Age ≥ 18 years\n* Awaiting trial (i.e., not sentenced)\n* English speaking\n* Diagnosis of active HCV (HCV RNA \\>1000 IU\u002FmL within 90 days prior to study entry)\n* Treatment-naïve for current HCV infection\n* No cirrhosis (FIB-4 Score \\\u003C3.25 within 90 days prior to study entry)\n* Self-report of injection drug use\n* Ability and willingness to be contacted after jail release\n* Verbal commitment to continue medication after discharge\n* Desire to receive Sofosbuvir\u002FVelpatasvir (Epclusa)\n\nExclusion Criteria:\n\n* Cirrhosis (FIB-4 Score \\>3.25 within 90 days prior to study entry and\u002For clinical signs of cirrhosis)\n* Positive for Hepatitis B surface antigen\n* Actively pregnant or breastfeeding\n* Known allergy\u002Fsensitivity to study drug components\n* Acute or serious illness requiring hospitalization at enrollment\n* Documented severe persistent mental illness (SPMI) by RIDOC\n* Any clinical history of hepatic decompensation (e.g., ascites, SBP, HE, HRS, variceal bleeding)\n* HIV-positive with active or acute AIDS-defining opportunistic infection within 90 days",{"count":138,"type":21},40,[88],"The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HCV and are awaiting trial.\n\nThe study asks:\n\n* Can a simplified, low-barrier HCV treatment program work in a jail setting?\n* Do participants finish treatment and get cured using this approach?\n\nAll participants will receive a 12-week course of the HCV medication sofosbuvir\u002Fvelpatasvir (Epclusa). If they are released before completing treatment, they will take the remaining doses with them. Community Health Workers (CHWs) will help support participants after release, including reminding them to take medications and helping them get follow-up lab work.\n\nResearchers will measure:\n\n* Whether participants are cured of HCV\n* Whether the treatment approach is easy to use (feasible), acceptable, and followed correctly (fidelity)\n* Whether the program could be used in other jails or expanded in the future\n\nThis study may help bring HCV treatment to more people in jail, reduce community spread of the virus, and support national goals to eliminate HCV.",[27,142,143,144],"Incarceration","Injection Drug Use","Implementation Science",[146,147,148,149,150,151,152],"hepatitis c","incarceration","jail","injection drug use","minimal monitoring","MINMON","implementation science","2026-02-26",{"date":155,"type":32},"2026-02-27",{"date":157,"type":32},"2025-06-11",{"date":159,"type":21},"2027-08",{"name":161,"class":39},"Lifespan",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":113,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":40},"100617366","rapid-hiv-hep-c-and-syphilis-screening-in-a-rural-street-medicine-clinic-100617366","NCT07317687","Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic","Rapid HIV, Hepatitis C, and Syphilis Screening in a Rural Street Medicine Clinic in West Virginia","Inclusion Criteria:\n\n* Patients of the WVU Medicine Street Medicine team\n\nExclusion Criteria:\n\n* Patients under the age of 18",{"count":170,"type":21},200,"OBSERVATIONAL","West Virginia faces rising rates of HIV, hepatitis, and syphilis, particularly among individuals experiencing homelessness, substance use, and mental health challenges. Traditional blood-draw testing for these infections is often hindered by mistrust, logistical barriers, and delays in results. This study, conducted by the West Virginia University (WVU) Street Medicine program, evaluates a rapid, point-of-care fingerstick test for HIV, Hepatitis C, and syphilis that provides results within 10-20 minutes during mobile clinic visits. Participants may choose rapid testing, traditional blood draw (which also includes Hepatitis B screening), or decline testing. All participants will be invited to complete a brief survey about the experiences with screening methods. The goal is to assess whether rapid testing improves screening uptake, linkage to care, and patient satisfaction, ultimately reducing barriers and disease burden in high-risk populations.",[174,27,175,92],"HIV Testing","Syphilis",[177,178],"Street Medicine","Rapid Fingerstick Testing","2026-01-15",{"date":181,"type":32},"2026-01-20",{"date":183,"type":21},"2026-01",{"date":185,"type":21},"2028-01",{"name":187,"class":39},"West Virginia University",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":113,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":40},"100577546","trauma-informed-resilience-based-telehealth-intervention-for-improving-hiv-prevention-and-hcv-care-for-persons-who-inject-drugs-in-the-deep-south-pilot-testing-aim3-100577546","NCT06799702","Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)","Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South","Inclusion Criteria:\n\n* People who actively inject drugs verified by visible injection stigmata (needle tracks)\n* HIV negative\n* Adult (≥18 years)\n* lives in rural areas\n\nExclusion Criteria:\n\n* Living with HIV\n* Lives in urban areas\n* Not proficient in English",{"count":48,"type":21},[24],"Evaluate the feasibility, acceptability, and usability of the intervention (primary outcomes) and coping skills and resilience (secondary outcomes) of the telehealth intervention over two months (8 weekly sessions) in a waitlist-controlled, randomized pilot trial using a cross-over design among 40 PWID. The primary outcomes will be feasibility, acceptability, and usability of the intervention. Secondary outcomes will be increased coping skills and resilience, which in turn, will increase status neutral HIV and HCV care and MOUD uptake (longer-term outcomes). Outcomes will be assessed using pre- and post-intervention surveys.",[199,27,52],"HIV Pre-exposure Prophylaxis",[201,202,203,58,204,205],"HIV Pre-Exposure Prophylaxis","Hepatitis C Virus","Medications for Opioid Use Disorder","Deep South","Telehealth Intervention","2025-12-17",{"date":208,"type":32},"2025-12-18",{"date":101,"type":21},{"date":211,"type":21},"2028-07-31",{"name":213,"class":39},"University of Georgia",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":222,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":230,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":244},"100595931","community-screening-and-management-of-hepatitis-b-c-and-delta-in-the-mongolian-population-living-in-france-100595931","NCT07038863","Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France","Community Screening for Hepatitis B, C and Delta in the Mongolian Population Living in France","Mondelta","Inclusion Criteria:\n\n* Mongolian people\n* Over 15 years of age\n* Living in France\n* Majors agree to participate or minors whose parental guardians agree to their child's participation in the study\n\nExclusion Criteria:\n\n* People already followed for viral hepatitis, treated or not treated\n* Persons deprived of their liberty by a judicial or administrative decision\n* Adults subject to a legal protection measure (guardianship, curators)\n* People participate in any interventional research except routine care research (old regulation) and category 2 research that does not interfere with the primary endpoint analysis","15 Years",{"count":115,"type":21},[24],"In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%, and hepatitis Delta (HDV) at 40-60% in HBV-infected patients. Viral hepatitis are essentially asymptomatic and therefore require systematic screening for diagnosis. Once a diagnosis of chronic viral infection has been established, specific therapies are available to reduce the morbidity and mortality of these patients. A study carried out in California in the Mongolian community found an HBV prevalence of 9.7% and positive HDV serology in 41% of these patients.\n\nThere is a large Mongolian community in France, estimated at between 5,000 and 6,000 patients. Although the majority of these patients are covered by French social security; however, access to care and screening for viral hepatitis often remain difficult and insufficient for migrant or vulnerable populations in France The aim of this study is to screen the Mongolian community in France for viral hepatitis, and then initiate a program of care and treatment.",[27,92,227,228,229],"Hepatitis D","Hepatocellular Carcinoma (HCC)","Liver Fibrosis",[231,232,233,234],"HBV","HCV","HDV","HCC","2025-06-18",{"date":237,"type":32},"2025-06-26",{"date":239,"type":21},"2025-09-01",{"date":241,"type":21},"2028-05-01",{"name":243,"class":39},"Hospices Civils de Lyon",11,{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":40},"100563968","accupower--hcv-performance-evaluation-quant-kit-bioneer-existationfa-96384-100563968","NCT06623058","Accupower ® HCV Performance Evaluation Quant Kit Bioneer Existation™FA 96\u002F384","BIOPERF-HCV","Inclusion Criteria:\n\nThe patient to be included in this study must be able to understand the purpose of the research, in order to to give free and informed consent.\n\n* Subject aged over 18\n* Subject presenting at the investigation center and meeting one of these two criteria:\n\n  * Subject presenting with a prescription for HCV viral load determination\n  * Subject whose HCV infection is previously confirmed by CE marked tests.\n* Subject capable of understanding the purpose of the research having given express free and informed consent\n* Subject affiliated to or beneficiary of a social security system\n\nExclusion Criteria:\n\nProtected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial decision or administrative Subject participating in a clinical study\u002Freceiving investigational treatment\n\n\\-",{"count":253,"type":21},45,"As part of the CE marking of a hepatitis C diagnostic kit, the South Korean manufacturer Bioneer wishes to set up a performance study in France in accordance with the IVDR (RE 2017\u002F746).\n\nCerba Xpert CRO of the Cerba Healthcare group promoted this performance study by setting up a prospective collection of blood samples from patients suffering from the virus hepatitis C and whose viral load is positive. This prospective collection will be carried out in 4 laboratories of the Cerba Healthcare group.",[27],"2024-10-02",{"date":258,"type":32},"2024-10-03",{"date":260,"type":21},"2024-10-01",{"date":262,"type":21},"2025-05-30",{"name":264,"class":39},"CerbaXpert",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":113,"sex":17,"minAge":272,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":4},"100562623","lay-user-evaluation-of-the-panbio-hcv-self-test-100562623","NCT06605573","Lay User Evaluation of the Panbio™ HCV Self-Test","Lay User Evaluation of the Panbio™ HCV Self Test: a Prospective, Multi-centre Observed Untrained User Study.","Inclusion Criteria:\n\n* Participant is aged 14 or over\n* Participant agrees to all aspects of the study and is able and willing to provide informed consent \u002F assent with parental consent.\n\nExclusion Criteria:\n\n* Participant has already participated in this study on a previous occasion.\n* Participant is aware of their HCV status\n* Participant is deemed unfit for the study by the Investigator.\n* Participant has a condition deemed unfit by the Investigator to safely perform or receive the test.\n* Participant is a practising health-care professional or laboratory scientist \u002F technician or has prior medical or laboratory training or experience\n* Participant is currently enrolled in a study to evaluate an investigational drug or vaccine.\n* Participant has a visual impairment that cannot be restored using glasses or contact lenses or is unable to read the Instructions for Use.\n* Participant is unwilling or unable to provide informed consent.\n* Participant has participated in the study \"Lay user evaluation of the Panbio™ HCV Self Test: A prospective, multi-centre usability study to evaluate lay user labelling comprehension and test result interpretation\".","14 Years",{"count":274,"type":21},1185,[24],"This is a prospective, multi-centre study designed to evaluate the usability of the Panbio™ HCV Self Test, when performed by untrained lay users in an observed study setting. The Panbio™ HCV Self Test detects antibodies to Hepatitis C Virus (HCV). The study validation will be conducted in accordance with the World Health Organisation's technical guidance on Hepatitis C rapid diagnostic tests for professional use and\u002For self-testing (TSS-16).",[27],[279,280,281,282,283],"diagnostics","rapid test","untrained user","hepatitis C","lateral flow test","2024-09-18",{"date":286,"type":32},"2024-09-20",{"date":288,"type":21},"2024-10",{"date":290,"type":21},"2025-03",{"name":292,"class":293},"Abbott Rapid Dx","INDUSTRY"]